查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1611323

類風濕性關節炎診斷測試市場：按測試類型、最終用戶分類 - 2025-2030 年全球預測

Rheumatoid Arthritis Diagnosis Tests Market by Test Type (Monitoring Rheumatoid Arthritis Treatment Efficiency Tests, Serology Test), End-User (Diagnostic Centers, Hospitals & Clinics) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

類風濕性關節炎診斷測試市場2023年估值為29.8億美元，預計2024年將達30.8億美元，複合年成長率為4.69%，預計到2030年將達到41.1億美元。

類風濕性關節炎(RA) 診斷測試包括一系列診斷程序，旨在檢測 RA（一種影響關節的慢性自體免疫疾病）的存在和進展。進行這些檢查的必要性源於 RA 對生活品質的影響，以及如果不治療可能導致關節損傷和全身併發症的可能性。主要應用包括類風濕因子 (RF) 等血液檢測、抗環瓜氨酸肽 (抗 CCP) 抗體檢測以及 X 光和 MRI 等影像檢查。最終用途廣泛，包括醫院、診斷實驗室和學術研究機構。推動市場成長的主要因素是 RA 盛行率的增加、診斷技術的改進以及患者和醫療保健提供者意識的提高。人口老化和生物標記的進步也有助於市場擴張。新的商機存在於快速、準確和微創診斷測試的開發以及遠端監控的遠端醫療應用的擴展中。

主要市場統計
基準年[2023] 29.8億美元
預計年份 [2024] 30.8億美元
預測年份 [2030] 41.1億美元
複合年成長率（%） 4.69%

然而，先進診斷測試的高成本、誤報和漏報的風險以及低收入地區的意識低等挑戰正在阻礙市場成長。報銷問題也會限制測試的機會。為了應對這些挑戰，技術創新應專注於具有成本效益的診斷解決方案，提高測試的敏感性和特異性，並透過數位健康平台擴大患者的訪問範圍。診斷公司、醫療保健提供者和科技公司之間的合作可以促進診斷準確性和可近性的顯著提高。同時，透過專注於利用人工智慧和基因研究的個人化醫療保健，我們可以期待量身定做的 RA 管理。新型生物標記的研究和多組體學方法的整合也為創新提供了肥沃的土壤。市場是競爭性的、技術主導的，因此投資新技術、優先考慮夥伴關係關係並解決地區健康差異的公司可能會增強其市場地位。總之，RA 診斷測試市場有望透過技術進步和策略措施實現成長，同時面臨成本和可近性方面的挑戰。

市場動態：快速發展的類風濕性關節炎診斷測試市場的關鍵市場洞察

供需的動態交互作用正在改變類風濕性關節炎診斷測試市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球類風濕性關節炎盛行率不斷上升
    • 增加 RA 治療和管理的支出
    • 政府和全球組織針對 RA 所進行的宣導活動
  • 市場限制因素
    • 患者不願接受 RA 醫療服務
  • 市場機會
    • 改進 MRI、超音波和 HR-pQCT影像檢查並開發血清生物標記組
    • 正在進行的 RA 診斷研究活動
  • 市場挑戰
    • 檢測套組的特異性和敏感性的限制

波特五力：開拓類類風濕性關節炎診斷測試市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對類風濕性關節炎診斷測試市場的影響

外部宏觀環境因素在塑造類風濕性關節炎診斷測試市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解類風濕性關節炎診斷檢測市場的競爭狀況

對類風濕性關節炎診斷測試市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣類風濕性關節炎診斷測試市場供應商績效評估

FPNV 定位矩陣是評估類風濕性關節炎診斷測試市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪類風濕性關節炎診斷測試市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對類風濕性關節炎診斷測試市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地類風濕性關節炎的盛行率正在增加。
      • 增加 RA 治療和管理的支出
      • 政府和國際組織進行有關 RA 的宣傳活動
    • 抑制因素
      • 患者不願接受 RA 醫療服務
    • 機會
      • 改進 MRI、超音波和 HR-pQCT影像檢查並開發血清生物標記組
      • 正在進行的 RA 診斷研究活動
    • 任務
      • 檢測套組特異性和敏感性的局限性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依測試類型類風濕性關節炎診斷測試市場

  • 類風濕性關節炎治療效果監測試驗
    • 肌酸酐測試
    • 肌酶測試
    • 水楊酸含量計數
  • 血清檢測
    • 抗環瓜氨酸肽
    • 抗核抗體
    • 紅血球沉積速率
    • 類風濕因子（RF）
    • 尿酸

第7章類類風濕性關節炎診斷測試市場：依最終用戶分類

  • 診斷中心
  • 醫院/診所

第8章北美和南美類風濕性關節炎診斷檢測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區類風濕性關節炎診斷檢測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲類風濕性關節炎診斷檢測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Apollo Health and Lifestyle Limited
  • Arthritis Society Canada
  • Augurex Life Sciences Corporation
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories Inc.
  • Exagen Inc.
  • F. Hoffmann-La Roche AG
  • Genway Biotech, Inc.
  • Laboratory Corporation of America Holdings
  • QIAGEN GmbH
  • Remission Medical
  • Siemens Healthineers
  • Svar Life Sciences AB
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-02026C4CB667

The Rheumatoid Arthritis Diagnosis Tests Market was valued at USD 2.98 billion in 2023, expected to reach USD 3.08 billion in 2024, and is projected to grow at a CAGR of 4.69%, to USD 4.11 billion by 2030.

Rheumatoid Arthritis (RA) diagnosis tests encompass a range of diagnostic procedures aimed at detecting RA's presence and progression, a chronic autoimmune disorder affecting joints. The necessity for these tests arises from RA's impact on quality of life and potential to cause joint damage and systemic complications if untreated. Key applications include blood tests such as rheumatoid factor (RF), anti-cyclic citrullinated peptide (anti-CCP) antibody testing, and imaging tests like X-rays and MRIs. End-use spans across hospitals, diagnostic laboratories, and academic research institutes. Market growth is primarily driven by increasing RA prevalence, improvements in diagnostic technologies, and heightened awareness among patients and healthcare providers. The aging population and advancements in biomarkers contribute to market expansion. Emerging opportunities exist in developing rapid, accurate, minimally invasive diagnostic tests, and expanding telemedicine applications for remote monitoring.

KEY MARKET STATISTICS
Base Year [2023] USD 2.98 billion
Estimated Year [2024] USD 3.08 billion
Forecast Year [2030] USD 4.11 billion
CAGR (%) 4.69%

However, market growth is impeded by challenges such as high costs of advanced diagnostic tests, risk of false positives or negatives, and limited awareness in low-income regions. Reimbursement issues can also limit test accessibility. To address these challenges, innovation should focus on cost-effective diagnostic solutions, enhancing the sensitivity and specificity of the tests, and increasing patient access through digital health platforms. Collaboration between diagnostic companies, healthcare providers, and technology firms can foster breakthroughs in diagnostic accuracy and accessibility. Concurrently, a focus on personalized healthcare using AI and genetic research holds promise for tailored RA management. Research into novel biomarkers and integration of multi-omic approaches also represents fertile ground for innovation. As the market is competitive and technology-driven, businesses that invest in emerging technologies, prioritize partnerships, and address regional healthcare disparities could strengthen their market position. In summary, the RA diagnosis test market is poised for growth through technological advancements and strategic initiatives despite facing challenges related to cost and accessibility.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Rheumatoid Arthritis Diagnosis Tests Market

The Rheumatoid Arthritis Diagnosis Tests Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of rheumatoid arthritis worldwide
    • Growing expenditure for the treatment and management of RA
    • Awareness initiatives about RA by governments and global institutions
  • Market Restraints
    • Patients' reluctance to access healthcare services for RA
  • Market Opportunities
    • Improvements in MRI, ultrasound, and HR-pQCT imaging tests and development of serum biomarker panel
    • Ongoing research activities for the diagnosis of RA
  • Market Challenges
    • Limited specificity and sensitivity of test kits

Porter's Five Forces: A Strategic Tool for Navigating the Rheumatoid Arthritis Diagnosis Tests Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Rheumatoid Arthritis Diagnosis Tests Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Rheumatoid Arthritis Diagnosis Tests Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Rheumatoid Arthritis Diagnosis Tests Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Rheumatoid Arthritis Diagnosis Tests Market

A detailed market share analysis in the Rheumatoid Arthritis Diagnosis Tests Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Rheumatoid Arthritis Diagnosis Tests Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Rheumatoid Arthritis Diagnosis Tests Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Rheumatoid Arthritis Diagnosis Tests Market

A strategic analysis of the Rheumatoid Arthritis Diagnosis Tests Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Rheumatoid Arthritis Diagnosis Tests Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Apollo Health and Lifestyle Limited, Arthritis Society Canada, Augurex Life Sciences Corporation, Beckman Coulter, Inc., Bio-Rad Laboratories Inc., Exagen Inc., F. Hoffmann-La Roche AG, Genway Biotech, Inc., Laboratory Corporation of America Holdings, QIAGEN GmbH, Remission Medical, Siemens Healthineers, Svar Life Sciences AB, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Rheumatoid Arthritis Diagnosis Tests Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test Type, market is studied across Monitoring Rheumatoid Arthritis Treatment Efficiency Tests and Serology Test. The Monitoring Rheumatoid Arthritis Treatment Efficiency Tests is further studied across Creatinine Test, Muscle Enzyme Tests, and Salicylate Level Count. The Serology Test is further studied across Anti-Cyclic Citrullinated Peptide, Antinuclear Antibody, Erythrocyte Sedimentation Rate, Rheumatoid Factor (RF), and Uric Acid.
  • Based on End-User, market is studied across Diagnostic Centers and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of rheumatoid arthritis worldwide
      • 5.1.1.2. Growing expenditure for the treatment and management of RA
      • 5.1.1.3. Awareness initiatives about RA by governments and global institutions
    • 5.1.2. Restraints
      • 5.1.2.1. Patients' reluctance to access healthcare services for RA
    • 5.1.3. Opportunities
      • 5.1.3.1. Improvements in MRI, ultrasound, and HR-pQCT imaging tests and development of serum biomarker panel
      • 5.1.3.2. Ongoing research activities for the diagnosis of RA
    • 5.1.4. Challenges
      • 5.1.4.1. Limited specificity and sensitivity of test kits
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Rheumatoid Arthritis Diagnosis Tests Market, by Test Type

  • 6.1. Introduction
  • 6.2. Monitoring Rheumatoid Arthritis Treatment Efficiency Tests
    • 6.2.1. Creatinine Test
    • 6.2.2. Muscle Enzyme Tests
    • 6.2.3. Salicylate Level Count
  • 6.3. Serology Test
    • 6.3.1. Anti-Cyclic Citrullinated Peptide
    • 6.3.2. Antinuclear Antibody
    • 6.3.3. Erythrocyte Sedimentation Rate
    • 6.3.4. Rheumatoid Factor (RF)
    • 6.3.5. Uric Acid

7. Rheumatoid Arthritis Diagnosis Tests Market, by End-User

  • 7.1. Introduction
  • 7.2. Diagnostic Centers
  • 7.3. Hospitals & Clinics

8. Americas Rheumatoid Arthritis Diagnosis Tests Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Rheumatoid Arthritis Diagnosis Tests Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Rheumatoid Arthritis Diagnosis Tests Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Apollo Health and Lifestyle Limited
  • 3. Arthritis Society Canada
  • 4. Augurex Life Sciences Corporation
  • 5. Beckman Coulter, Inc.
  • 6. Bio-Rad Laboratories Inc.
  • 7. Exagen Inc.
  • 8. F. Hoffmann-La Roche AG
  • 9. Genway Biotech, Inc.
  • 10. Laboratory Corporation of America Holdings
  • 11. QIAGEN GmbH
  • 12. Remission Medical
  • 13. Siemens Healthineers
  • 14. Svar Life Sciences AB
  • 15. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET RESEARCH PROCESS
  • FIGURE 2. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET DYNAMICS
  • TABLE 7. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CREATININE TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MUSCLE ENZYME TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SALICYLATE LEVEL COUNT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTI-CYCLIC CITRULLINATED PEPTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTINUCLEAR ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ERYTHROCYTE SEDIMENTATION RATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY RHEUMATOID FACTOR (RF), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY URIC ACID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET, FPNV POSITIONING MATRIX, 2023